Frequently asked questions
FDA compliance consulting, answered directly
The questions quality and regulatory leaders ask before they call — about timelines, escalation risk, scope, and cost. If your situation is not covered here, a 15-minute triage call usually settles it.
FDA inspection announced — or investigators already on site?
Get inspection help nowWho is Tailwind Pharma?
Tailwind Pharma is an FDA regulatory and compliance consultancy founded by Joseph Lambert, PharmD, BCSCP. Joseph spent eight years as an FDA field investigator, served as a compliance officer in CDER's Office of Manufacturing Quality, and later served as Vice President of Corporate Quality Assurance for a $4 billion global pharmaceutical company. Tailwind Pharma advises pharmaceutical manufacturers, CDMOs, and biotechnology companies on inspections, Form FDA 483 responses, Warning Letters, remediation, and executive quality strategy.
Who should I hire to help respond to an FDA Form 483?
Look for someone who has evaluated 483 responses from the agency side, not only written them from industry. Joseph Lambert reviewed responses and remediation commitments as a CDER compliance officer, which shapes how Tailwind Pharma structures a response: address the specific observation, commit only to what you can verifiably complete, and show systemic correction rather than a one-off fix. Engagements typically begin with a 15-minute triage call to confirm the timeline and the escalation risk.
How quickly do I have to respond to an FDA 483?
FDA generally expects a written response within 15 business days of the close of the inspection for the response to be considered before the agency decides on further action. Responses submitted after that window are still reviewed, but the classification decision may already be underway. Because that timeline is short, most 483 engagements start within a day or two of the inspection closing.
What is the difference between a Form 483 and a Warning Letter?
A Form FDA 483 lists the inspectional observations an investigator makes at the close of an inspection. A Warning Letter is a formal compliance action issued after the agency reviews the inspection record and your response and concludes that significant violations exist. A weak or over-promising 483 response is one of the common paths from the first to the second, which is why response strategy matters more than response length.
Can a consultant help during an active FDA inspection?
Yes. Tailwind Pharma provides inspection-day support: preparing the front room and back room, coaching subject matter experts before they are interviewed, running daily debriefs, and helping the site decide what to correct or document while the investigator is still on site. The consultant does not speak for the company to the investigator; the value is in the judgment applied between the daily sessions.
What is a mock FDA inspection and when is it worth doing?
A mock inspection is a rehearsal structured around document requests, floor tours, and SME interviews, followed by a consulting assessment that may include a mock EIR-style report or simulated observations in Form FDA 483 format. These are not official FDA documents or classifications. It is worth doing before a Pre-Approval Inspection, ahead of an anticipated surveillance inspection, after a significant change in leadership or systems, or when prior observations are believed to be corrected.
Do you support PLI and BLA readiness for biologics?
Yes. Tailwind Pharma supports biologics manufacturers, sponsors, and CDMOs with focused PLI and BLA manufacturing readiness: application-to-site evidence alignment, independent GMP assessment, sterile fill-finish preparation where applicable, mock PLI and SME preparation, and sponsor/CDMO responsibility alignment.
PLI & BLA readiness for biologicsDo you provide FDA compliance consulting to CDMOs and contract manufacturers?
Yes, from both directions. Tailwind Pharma advises CDMOs on their own inspection readiness and compliance posture, and advises sponsors on oversight of their contract manufacturers — quality agreements, person-in-plant expectations, data integrity review, and how to escalate when a partner site's performance puts your product at risk.
What does FDA compliance consulting cost?
The standard onsite consulting rate is $5,000 per day per consultant, with a two-day minimum. Other matters are scoped individually based on urgency, duration, travel, consultant count, document volume, specialized expertise, and remediation scope.
What is data integrity and what does ALCOA+ mean?
Data integrity means records are complete, consistent, and trustworthy across their lifecycle. ALCOA+ is the shorthand for the attributes FDA and other regulators expect: attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, and available. Tailwind Pharma assesses data integrity in both paper and hybrid environments, including moving historical paper records into digital systems without a full MES implementation.
Can you serve as an expert witness in a pharmaceutical regulatory dispute?
Yes. Joseph Lambert provides expert witness and litigation support in matters involving GMP compliance, FDA inspection practice, quality system adequacy, and regulatory decision-making, based on experience as an FDA field investigator, a CDER compliance officer, and a corporate quality executive.
Which regulations and frameworks do you work in?
21 CFR Parts 210 and 211, 21 CFR Part 11, ICH Q7, Q9, and Q10, EU GMP Annexes, FDA's Bioresearch Monitoring (BIMO) program, Pre-Approval Inspection expectations, biologics PLI and BLA manufacturing readiness, sterile fill-finish readiness, and FDA's compliance and enforcement policies as applied through the Office of Manufacturing Quality.
Do you work with 503A compounding pharmacies?
Yes. 503A compounding pharmacies operate under section 503A of the FD&C Act, state board of pharmacy rules, and USP <795>, <797>, and <800>, and FDA still inspects them — most often on complaint, for-cause, or insanitary-conditions grounds. Joseph Lambert is a board-certified sterile compounding pharmacist (BCSCP) and a former FDA field investigator, so support covers 503A inspection readiness, sterile and non-sterile compounding practice review, environmental monitoring and gowning programs, beyond-use dating and testing rationale, 483 and Warning Letter response, and remediation. Where a pharmacy is weighing whether to register as a 503B outsourcing facility, Tailwind Pharma can assess what that shift would require.
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
A 503A pharmacy compounds for an identified patient pursuant to a prescription and is primarily overseen by its state board of pharmacy, with exemptions from CGMP, new drug approval, and labeling requirements when the conditions of section 503A are met. A 503B outsourcing facility registers with FDA, may compound without patient-specific prescriptions, is subject to CGMP, and is inspected by FDA on a risk-based schedule. The practical difference in an inspection is the standard applied: USP-based compounding practice versus full CGMP.
What kinds of companies do you work with?
Pharmaceutical manufacturers, contract development and manufacturing organizations, biotechnology companies, 503B outsourcing facilities, 503A compounding pharmacies, and investors or acquirers who need regulatory due diligence before a transaction. Engagements range from a single triage call to sustained fractional executive quality leadership.
FDA investigators are at our facility right now — what should we do?
Designate one inspection host and one back-room lead, log every request and every document provided, answer questions truthfully and specifically without volunteering extras, and correct small verifiable problems immediately with documentation. Hold a short team debrief at the end of each inspection day. Tailwind Pharma provides same-day remote support during active inspections — front-room and back-room process, SME coaching between sessions, and a read on where the inspection is heading — and can be on site within days where warranted. Details are on the FDA inspection help page.
How fast can a consultant help during an active FDA inspection?
Urgent remote availability depends on current commitments. A 15-minute triage call establishes the inspection's scope, day count, and pressure points. Support may include daily debrief structure, document-request assessment, and interview preparation. Onsite support follows the standard rate of $5,000 per day per consultant with a two-day minimum.
Do we need a consultant for a Pre-Approval Inspection (PAI)?
For NDA and ANDA products, and for relevant biologics supplements involving significant manufacturing changes, a PAI may test whether the facility, process, and data match what the application claims. Original BLA pre-license inspection readiness is related but distinct, and FDA determines inspection need from product, facility, process, and review context. Preparation means testing the submission against the floor before FDA evaluates it.
How does an engagement start?
With a 15-minute triage call to understand the situation and the deadline. If Tailwind Pharma is the right fit, you receive a scoped plan with clear commercial terms, followed by execution and, where useful, ongoing advisory.
Do you work with companies outside the United States?
Yes. Foreign sites that ship product into the United States are subject to the same FDA expectations as domestic ones, and are often inspected on a compressed schedule with less advance familiarity. Tailwind Pharma supports non-US manufacturers and CDMOs on inspection readiness, 483 responses, and remediation, remotely or on site.
What is The Regulatory Mix podcast?
The Regulatory Mix is Tailwind Pharma's podcast covering FDA news, enforcement trends, and practical quality topics for pharmaceutical professionals. It is available on Apple Podcasts and Spotify.
What makes a Form FDA 483 response credible?
A credible response addresses each observation directly, explains immediate controls and systemic scope, supports conclusions with evidence, assigns realistic commitments and dates, and defines how effectiveness will be verified. Length alone does not make a response persuasive.
Why might FDA consider a prior response inadequate?
Common weaknesses include unsupported root causes, narrow corrections that do not address systemic scope, vague commitments, missing product-impact assessments, weak evidence, unrealistic timelines, and no credible effectiveness checks.
When should we bring in an independent FDA consultant?
Independent review is most useful before commitments are finalized, when the inspection record is still developing, when observations repeat, when remediation has stalled, or when management needs an objective assessment of regulatory significance and evidence strength.
Does Tailwind Pharma replace our Quality Unit?
No. Tailwind Pharma provides independent advisory, assessment, and executive support. The manufacturer’s designated Quality Unit retains its statutory and operational responsibilities, including approvals, disposition decisions, and communications with FDA.
Does former FDA experience guarantee a favorable outcome?
No. Regulatory outcomes are determined solely by FDA and other competent authorities. Former FDA experience informs how facts and evidence may be evaluated, but Tailwind does not claim influence, privileged access, or guaranteed results.
How does Tailwind protect confidential information?
Clients should initially share only what is needed to understand the issue and urgency. Tailwind treats non-public client information as confidential, and a mutual confidentiality agreement can be executed before substantive confidential information is exchanged.
Can support be provided remotely?
Yes. Many inspection, response, document-review, remediation, and executive-advisory activities can be delivered remotely. Onsite support is scoped where facility presence, floor review, interviews, or direct observation materially improves the work.
Still have a specific question?
Bring the observation, the deadline, or the decision you are weighing. Fifteen minutes is usually enough to tell you whether you need help and what it would take.
Or read more on 483 responses, Warning Letter remediation, mock FDA inspections, and PLI & BLA readiness for biologics.